MTOR and breast carcinoma: Collectively, these results are in agreement with previous studies demonstrating an association between low expression of hamartin or tuberin and poor breast cancer clinical outcome [24], between enhanced AKT-mTOR signaling and poor post-relapse breast cancer survival [60], and between depletion of tuberin in mice and breast cancer progression and metastasis [25].